Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
Ahmed O. Hassan, Friederike Feldmann, Haiyan Zhao, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 4, pp. 100230-100230
Open Access | Times Cited: 122

Showing 1-25 of 122 citing articles:

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Rita E. Chen, Xianwen Zhang, James Brett Case, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 717-726
Open Access | Times Cited: 970
After the pandemic: perspectives on the future trajectory of COVID-19
Amalio Telenti, Ann M. Arvin, Lawrence Corey, et al.
Nature (2021) Vol. 596, Iss. 7873, pp. 495-504
Open Access | Times Cited: 388
Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
Sam Afkhami, Michael R. D’Agostino, Ali Zhang, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 896-915.e19
Open Access | Times Cited: 264
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Tianyang Mao, Benjamin Israelow, Mario A. Peña-Hernández, et al.
Science (2022) Vol. 378, Iss. 6622
Open Access | Times Cited: 238
Intranasal COVID-19 vaccines: From bench to bed
Aqu Alu, Li Chen, Lei Hong, et al.
EBioMedicine (2022) Vol. 76, pp. 103841-103841
Open Access | Times Cited: 208
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
Alexandra C. Walls, Kaitlin R. Sprouse, John E. Bowen, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 872-880.e3
Open Access | Times Cited: 197
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Young‐Jun Park, Dora Pinto, Alexandra C. Walls, et al.
Science (2022) Vol. 378, Iss. 6620, pp. 619-627
Open Access | Times Cited: 193
Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization
Dennis Lapuente, Jana Fuchs, Jonas Willar, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 183
Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine
Zhenzhen Wang, Kristen D. Popowski, Dashuai Zhu, et al.
Nature Biomedical Engineering (2022) Vol. 6, Iss. 7, pp. 791-805
Open Access | Times Cited: 178
Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
John E. Bowen, Amin Addetia, Ha V. Dang, et al.
Science (2022) Vol. 377, Iss. 6608, pp. 890-894
Open Access | Times Cited: 174
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice
Ahmed O. Hassan, Swathi Shrihari, Matthew J. Gorman, et al.
Cell Reports (2021) Vol. 36, Iss. 4, pp. 109452-109452
Open Access | Times Cited: 119
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
Meera Madhavan, Adam Ritchie, Jeremy Aboagye, et al.
EBioMedicine (2022) Vol. 85, pp. 104298-104298
Open Access | Times Cited: 106
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
Mattia Tiboni, Luca Casettari, Lisbeth Illum
International Journal of Pharmaceutics (2021) Vol. 603, pp. 120686-120686
Open Access | Times Cited: 104
Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2
Samantha Mackin, Pritesh Desai, Bradley Whitener, et al.
Nature Microbiology (2023) Vol. 8, Iss. 4, pp. 569-580
Open Access | Times Cited: 83
Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission
Michael W. Russell, Jiří Městecký
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 77
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges
Kuldeep Dhama, Manish Dhawan, Ruchi Tiwari, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 75
Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status
Vivek P. Chavda, Rajashri Bezbaruah, Disha Valu, et al.
Vaccines (2023) Vol. 11, Iss. 2, pp. 432-432
Open Access | Times Cited: 49
Mucosal vaccines for SARS-CoV-2: triumph of hope over experience
Devaki Pilapitiya, Adam K. Wheatley, Hyon‐Xhi Tan
EBioMedicine (2023) Vol. 92, pp. 104585-104585
Open Access | Times Cited: 47
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
Katherine McMahan, Frank Wegmann, Malika Aïd, et al.
Nature (2023) Vol. 626, Iss. 7998, pp. 385-391
Open Access | Times Cited: 40
SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
Michael Diamond, Rita Chen, Xuping Xie, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 86
Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2
Xingyue An, Melisa Martinez-Paniagua, Ali Rezvan, et al.
iScience (2021) Vol. 24, Iss. 9, pp. 103037-103037
Open Access | Times Cited: 77
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques
Hannah A. D. King, Michael Joyce, Inès Lakhal-Naouar, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 38
Open Access | Times Cited: 60
Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses
Tianyang Mao, Benjamin Israelow, Alexandra Suberi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 58
Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection
Basanth Babu Eedara, Wafaa Alabsi, David Encinas-Basurto, et al.
Pharmaceutics (2021) Vol. 13, Iss. 7, pp. 1077-1077
Open Access | Times Cited: 56
A chitosan-mediated inhalable nanovaccine against SARS-CoV-2
Shao‐Hua Zhuo, Jun Wu, Lang Zhao, et al.
Nano Research (2022) Vol. 15, Iss. 5, pp. 4191-4200
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top